Tuberculous meningitis is a devastating brain infection that is caused by Mycobacterium
tuberculosis and is notoriously difficult to diagnose and treat. New technologies …

Background and aim Tuberculosis (TB) is associated with a high mortality in the intensive
care unit (ICU), especially in subjects with Acute Respiratory Distress Syndrome (ARDS) …

Background High-dose rifampicin may improve outcomes of tuberculous meningitis (TBM).
Little safety or pharmacokinetic (PK) data exist on high-dose rifampicin in human …

Neuroradiological abnormalities in tuberculous meningitis (TBM) are common, but the exact
relationship with clinical and inflammatory markers has not been well established. We …

Background Intensified antimicrobial treatment with higher rifampicin doses may improve
outcome of tuberculous meningitis, but the desirable exposure and necessary dose are …

Background Recent evidence suggests that higher rifampicin doses may improve
tuberculosis (TB) treatment outcome. Methods In this observational cohort study we …

Background There is substantial variation in the reported treatment outcomes for adult
tuberculous meningitis (TBM). Data on survival and neurological disability by continent and …

Background Tuberculous meningitis (TBM) is the most lethal and disabling form of
tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is poorly …

Objective To assess the pharmacokinetics and safety/tolerability of isoniazid, rifampicin and
pyrazinamide in children and adolescents with tuberculous meningitis (TBM). Design …

Background Tuberculosis (TB) remains a significant cause of mortality globally, yet first-line
treatment has hardly changed for fifty years. The dose of rifampicin, the most important drug …